Retinal vein occlusion (RVO) is the second most
INTRODUCTION AND PATHOPHYSIOLOGY
Retinal vein occlusion (RVO) is currently the second most common cause of visual impairment due to retinal disease after diabetic retinopathy [1] . It is defined as a vascular disorder characterized by engorgement and dilatation of the retinal veins with secondary, mostly intraretinal hemorrhage, and retinal edema. Retinal ischemia, cotton wool spots, exudates, and macular edema can also be present [2] . The incidence of vein occlusion is 0.7% for the age group 49-60 years and 4.6% after 80 years of age, with no gender disparities [3] .
RVOs are classically divided into two groups by their location: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). In fact, although CRVOs involve the whole venous retinal system, in BRVO the venous engorgement involves only a branch of the retinal venous network. If only a hemisphere of the fundus is involved, the presumed site of the occlusion is one of the two trunks of an abnormally split intraneural central retinal vein.
This entity (hemicentral RVO) is considered a variant of CRVO [1, 2] . When the arteriovenous crossing is located on or close to the optic disc, a hemispheric RVO can develop, extending to a hemiretina. CRVO is presumably determined by an increased venous outflow resistance located at the lamina cribrosa level; this resistance is more distal in a BRVO. CRVO can be limited to a small artery crossing a small macular vein, or involve a whole quadrant when occurring at the edge of the optic nerve. BRVO occurs at retinal arteriovenous crossing sites, where the vein shares the adventitia with the artery; thus, being vulnerable to its compression.
Fluorescein angiography has demonstrated turbulent blood flow at these sites; thus, leading to a predisposition toward endothelial damage and thrombus formation [4] . In eyes affected by the advanced stages of CRVO, histopathologic studies show a thrombus placed at or just posterior to the lamina cribrosa [5] . The main hypothesis explains its formation as the central retinal vein is compressed by the central artery at the tract where a common fibrous sleeve is shared [6] .
METHODS
The [8] .
Loss of VA is usually more pronounced with ischemic compared with nonischemic CRVO, although vision also tends to be poor in eyes with nonischemic CVRO [2, 9] .
At presentation, patients with BRVO complain of blurred vision from retinal hemorrhage or macular edema. Occasionally, subjective spots, strands, or curtains may occur due to vitreous hemorrhage. VA is generally worse than 20/40 [7] [8] [9] .
RISK FACTORS
Major cardiovascular risk factors, such as diabetes, hypertension, and dyslipidemia, are more often associated with RVO, whereas minor risk factors, such as smoking and high body mass index, show a less consistent linkage to RVO [10, 11] .
Open-angle glaucoma is the main ophthalmological risk factor; the increased intraocular pressure reduces the retinal venous outflow, leading to flow stasis. It is clearly associated with CRVO [12, 13] , while only one study reveals a statistically significant linkage to BRVO [14] . To date, the role of thrombophilic defects is controversial. As revealed by two meta-analyses, the factor V Leiden mutation clearly increases the risk of RVO by approximately 50-60% [1, 15] .
Interestingly, other rather common prothrombotic defects, such as deficiencies of antithrombin and protein C or S, are not associated with RVO [15] . The role of lupus anticoagulant factor and anticardiolipin antibodies have not been fully understood, but their relationship with RVO seems to be weak so far [7, 16] .
Some studies suggest that patients suffering from RVO could have an underlying genetic predisposition [2, 7] . In fact, as RVO occurs where the blood flow is locally turbulent, 
NATURAL HISTORY
After a CRVO has occurred, VA is usually poor and tends to remain impaired during follow-up, despite therapeutic efforts. It has been reported that at least 75% of eyes with CRVO (ischemic and nonischemic) had a VA of 20/40 or worse after 12 months [8] . As mentioned previously, the presence and the extension of nonperfused retinal areas are correlated with bad visual outcome and higher rates of complication, such as neovascular glaucoma. It is, thus, essential to regularly monitor CRVO patients for ischemic areas using fluorescein angiography. A nonischemic CVRO may convert into an ischemic CVRO, and such an irreversible event is known to happen in up to 34% of cases after 3 years of follow-up [2, 8] , being more rapid during the first 4 months. Bevacizumab, a pan-VEGF blocker, is being widely used due to its relatively-low cost. after some studies reported acute optic nerve ischemia and visual loss after the procedure [40] . [47, 48] , but the exact mechanism is still unknown. It has been proposed that the removal of vitreous cytokines and VEGF, and the enhancing oxygen transport to the retina could play an important role [49, 50] . However, many studies did not confirm the benefits of this kind of surgery and the long-term effects are unknown [51] .
Some studies have promoted the administration of tissue plasminogen activator (t-PA) directly to the affected retinal vein to obtain a rapid lysis of the thrombus with a precise visualization of the occlusion site, and with the administration of a very small dose of drug [52] (level III). Visual improvement after this technique was reported in 54% of the 28 treated eyes [53] , but results still remain controversial.
Another proposed approach consists of the dissection of the common adventitial sheath at the level of the arteriovenous blockage site in patients affected by BRVO. Unfortunately, until now, most studies have failed to show a convincing improvement on outcomes in BRVO that could justify the risks of the surgical procedure [54, 55] 
